It was the third trigger of the recession indicator in less than two weeks.Bondsread more
Overstock CEO Partick Byrne has resigned from the e-commerce company after making controversial comments about his role in the "Deep State."Technologyread more
U.S. manufacturer growth slowed to the lowest level in almost 10 years in August, the latest sign that the trade war may be exacerbating the economic slowdown.Marketsread more
Automakers are trying to deal with President Trump's efforts to roll back Obama-era fuel efficiency rules.Autosread more
ARM rates are all over the place lender to lender because they are a very small percentage of new loan originations, around 6% of total mortgage application volume, according...Real Estateread more
"The president is not backing down," says CNBC's Jim Cramer, referring to Trump's repeated calls for the Fed to cut rates while talking tough on China.Economyread more
Philadelphia Fed President Patrick Harker said he doesn't see the case for additional stimulus after the Federal Reserve's July rate cut.The Fedread more
Stocks fell, giving up earlier gains as investors wondered whether the Federal Reserve will cut interest rates next month.US Marketsread more
"My sense was we've added accommodation, and it wasn't required in my view," George tells CNBC's Steve Liesman.Investingread more
Former Prudent Bear Fund manager David Tice is urging investors to brace for a massive downturn.Trading Nationread more
Samsung's Galaxy Note 10+ packs everything you need and more into a phone.Technologyread more
PARIS, July 29 (Reuters) - Sanofi raised its 2019 outlook on the back of second-quarter results lifted by double digit growth at its vaccines and rare diseases businesses.
The French drugmaker said on Monday that it was now eyeing earnings per share growth of around 5% compared to an earlier target range of 3-5%.
Second quarter business net income rose 4.9% at constant exchange rates to 1.64 billion euros ($1.82 billion) while sales were up 3.9% to 8.63 billion euros.
The company said it had booked an 1.8 billion euros impairment charge of intangible assets in the quarter related to hemophilia product Eloctate, after lower sales in the U.S. and a revision of sales projections.
Eloctate was developed by U.S. hemophilia specialist Bioverativ which Sanofi agreed to buy last year for $11.6 billion.
($1 = 0.8988 euros) (Reporting by Matthias Blamont; Editing by Sudip Kar-Gupta)